D. Western Therapeutics Institute, Inc.

TSE:4576 Stock Report

Market Cap: JP¥6.6b

D. Western Therapeutics Institute Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Yuichi Hidaka

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure16yrs
CEO ownership7.7%
Management average tenureno data
Board average tenure10.7yrs

Recent management updates

Recent updates

Health Check: How Prudently Does D. Western Therapeutics Institute (TSE:4576) Use Debt?

Nov 28
Health Check: How Prudently Does D. Western Therapeutics Institute (TSE:4576) Use Debt?

Is D. Western Therapeutics Institute (TSE:4576) Using Debt Sensibly?

May 23
Is D. Western Therapeutics Institute (TSE:4576) Using Debt Sensibly?

CEO

Yuichi Hidaka (51 yo)

16yrs

Tenure

Mr. Yuichi Hidaka has been President of D.Western Therapeutics Institute, Inc.(DWTI) since December 2008 and serves as its Chief Executive Officer. Mr. Hidaka serves as a Director at Actual Eyes Inc. He se...

Board Members

NamePositionTenureCompensationOwnership
Yuichi Hidaka
President16yrsno data7.69%
¥ 511.4m
Sayako Matsubara
CFO & Director1.8yrsno data0.015%
¥ 980.2k
Yoshiyuki Yamakawa
Independent Outside Director14.8yrsno data0.047%
¥ 3.2m
Eisaku Nakamura
Independent Outside Director6.7yrsno data0.00026%
¥ 17.3k
Masaaki Suzuki
Member of Scientific Advisory Boardno datano datano data
Tasuku Honjyo
Member of Scientific Advisory Boardno datano datano data
Masato Shibuya
Member of Scientific Advisory Boardno datano datano data
Arata Uemura
Member of Scientific Advisory Boardno datano datano data
Anthony Means
Member of Scientific Advisory Boardno datano datano data
Walter Chazin
Member of Scientific Advisory Boardno datano datano data
Yasuhiko Ito
Member of Scientific Advisory Boardno datano datano data
Yasumi Uchida
Member of Scientific Advisory Boardno datano datano data

10.7yrs

Average Tenure

56.5yo

Average Age

Experienced Board: 4576's board of directors are seasoned and experienced ( 10.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 01:10
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

D. Western Therapeutics Institute, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution